Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06323356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06323356 · ClinicalTrials.gov record · last posted 2026-07-30

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

StatusCompleted
PhasePhase 3
SponsorTakeda
Started2024-03-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Protocol amendment history 1 change detected by DataLookout

2026-07-31
Trial completed
Trial Details
NCT Number NCT06323356
Lead Sponsor Takeda
Conditions Generalized Pustular Psoriasis, Erythrodermic Psoriasis
Enrollment 18 participants
Start Date 2024-03-19
Primary Completion 2025-10-17 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-30